Daniel Rios Pinto Ribeiro, Eduardo Cambruzzi, Juliana Canedo Sebben, Karina Pezzi Melleu, Mareia Moura Schmidt, Carlos AM Gottschall, Alexandre Schaan de Quadros
ALTITUDE: Aliskiren Trial In Type 2 Diabetes Using Cardio Renal Endpoints.
Editorial Comment: Morbimortality in diabetic patients is still a matter of deep concern in the context of reduced cardiovascular mortality of recent years. Based on the proven clinical benefit of drugs such as ACEIs or ARBs in treating patients with renal failure, the study randomized 8700 treated with aliskiren or placebo, in a 32 month...
EXAMINE: The alogliptin is safe for treating type 2 diabetes in patients with a recent history of acute coronary syndrome.
Type 2 diabetes is associated both microvascular and macrovascular disease. Adequate glycemic control can reduce the risk of many microvascular complications but have not shown the same effect on macrovascular complications. This study evaluates the results of alogliptin compared with placebo in patients with type 2 diabetes who had a recent acute coronary syndrome. The...
Gastric bypass puts type 2 diabetes into remission
Original title: Effects of Ingestion Routes on Hormonal and Metabolic Profiles in Gastric-Bypassed Humans. Reference: Andreas Lindqvist, Peter Spégel, Mikael Ekelund, Hindrik Mulder, Leif Groop, Jan Hedenbro and Nils Wierup. . JCEM, 2013 DOI: 10.1210/jc.2012-3996. A team of researchers at Lund University has explained why gastric bypass often sends diabetes to fast remission, which could be a step...
Myocardial Damage in MAC
Mitral annulus calcification (MAC) affects between 8% and 23% of the population. It is more common in women and patients with renal insufficiency. This phenomenon is characterized by an increase in valvular annulus fibrosis, which can extend and affect the leaflets. The presence of MAC is associated with valve regurgitation or stenosis, increasing mortality and...
ULTIMATE III: Use of IVUS for Coronary De Novo Lesion Drug Coated Balloon Angioplasty
Percutaneous coronary intervention (PCI) with drug eluting stents (DES) can present limitations, especially in the form of stent thrombosis or instent restenosis (ISR). These findings have furthered the development of drub coated balloons (DCB). The safety and efficacy of DCB have already been shown in the context of ISR and de novo small vessel coronary...
Edge-to-Edge Repair for Right Ventricular Function Deterioration
Tricuspid regurgitation (TR) has been associated with worse survival and hospitalization for cardiac failure (CF). The current guidelines recommend surgery as treatment, despite its 8 – 15% 30-day mortality rate. And there is no mention of a transcatheter intervention, especially for patients with severe TR and right ventricular deterioration. Several percutaneous intervention devices have recently...
Cardioband in Tricuspid Valve Regurgitation
Untreated tricuspid regurgitation (TR) has been associated to high morbimortality. Surgical treatment of isolated severe TR is complex and carries a high mortality rate. A transcatheter treatment of this valve is currently being developed, and different concepts are being applied to the new devices. Even though most TR is secondary, atrial functional tricuspid regurgitation (A-FTR)...
2 Year Outcomes of Transcatheter Mitral Valve Replacement with Intrepid
Severe mitral valve insufficiency (MI) has been associated to the progressive deterioration of left ventricular function, cardiac and kidney failure, and increased mortality. Complete medical treatment at maximal doses and surgery are indicated. For those at high risk or those with ventricular function deterioration, edge-to-edge repair has been shown an excellent alternative. The use of...